Institute submits NDA for PET to diagnose Parkinsonian syndromes

11/15/2012 | MedicalXpress.com

The Feinstein Institute for Medical Research said it has submitted a new-drug application to the FDA for the use of 18F-fluorodopa-PET in diagnosing Parkinsonian syndromes. The FDA earlier this year approved the institute's use of the scan as part of an expanded access investigational new drug program.

View Full Article in:

MedicalXpress.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA